CAXTON CORP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001388551

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q3 2023 · 9 positions · Total reported value $26.32M · Top-10 concentration 100.0% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 38.5% · 3 new · 2 cut · 0 exited

Active Share (vs S&P 500): 94.7% · vs QQQ: 91.3% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -8.1% · vs SPY -10.2% · Prev Value $1.85M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -5.7% · vs SPY -7.8% · Latest Value $2.78M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2023 13F filing, CAXTON CORP disclosed 9 equity positions with a combined reported value of $26.32M. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2023 were SVRA ($12.53M), XERS ($10.49M), RZLT ($1.74M). By sector, the heaviest allocations are Health Care 95.2%, Other 4.8%.

Versus the prior quarter, CAXTON CORP opened 3 new positions, trimmed 2 and fully exited 0, a turnover rate of 38.5% of positions.

The largest new positions opened in Q3 2023 were SVRA ($12.53M), XERS ($10.49M), RZLT ($1.74M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2023)

  • SVRA SAVARA INC · $12.53M
  • XERS XERIS BIOPHARMA HOLDINGS INC · $10.49M
  • RZLT REZOLUTE INC · $1.74M
  • MTEM MOLECULAR TEMPLATES INC · $864.99K
  • APGE APOGEE THERAPEUTICS INC · $265.65K
  • CMPX COMPASS THERAPEUTICS INC · $170.94K
  • ACRS ACLARIS THERAPEUTICS INC · $133.39K
  • ALLK ALLAKOS INC · $111.98K

Fully Exited (vs previous quarter)

No tracked position was fully exited this quarter.

Insider Transactions (Form 4)

Latest CAXTON CORP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Caxton CORP files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 10 positions worth $1.85M in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Portfolio Structure

  • 10 positions · $1.85M reported value (Q2 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: SPCX (SPACE EXPLORATION TECHN CORP) at 24.0%
  • Average position size: $185.34K

Sector Tilt

  • Information Technology 37.3%
  • Health Care 19.6%
  • Financials 10.2%
  • (classified holdings cover 67% of value)

Quarterly Activity

  • Q2 2026: 4 new, 2 added, 1 reduced, 1 exited
  • 3 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 95.2%
Other 4.8%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 3.31M $12.53M 47.59%
47.59%
New
2 5.64M $10.49M 39.87%
39.87%
New
3 1.32M $1.74M 6.61%
6.61%
New
4 136.87K $864.99K 3.29%
3.29%
New
5 12.47K $265.65K 1.01%
1.01%
New
6 86.77K $170.94K 0.65%
0.65%
New
7 19.47K $133.39K 0.51%
0.51%
New
8 49.33K $111.98K 0.42%
0.42%
New
9 21.81K $14.45K 0.06%
0.06%
New

FAQ

What did CAXTON CORP buy in 2023-Q3?

In its 2023-Q3 13F filing, CAXTON CORP reported 9 equity positions worth $26.32M in aggregate; its largest disclosed positions were SVRA ($12.53M), XERS ($10.49M), RZLT ($1.74M).

How large is CAXTON CORP's portfolio?

CAXTON CORP reported $26.32M of long equity holdings across 9 positions as of 2023-Q3. Top-10 holdings account for 100.0% of reported value.

What is CAXTON CORP's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/caxton/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →